Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 11,571 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: CHRONIC DISEASE Clear all

Conditions: Posttraumatic Stress Disorder
Interventions: Midomafetamine HCl, Lactose placebo pill, Therapy; Drug · Behavioral
Lead sponsor: Resilient Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Mt. Pleasant, South Carolina

Conditions: Hypertension, Cognitive Decline
Interventions: Tai Chi; Behavioral
Lead sponsor: University of Connecticut; Other
Eligibility: 55 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 6 Months to 74 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 3
States / cities: Atlanta, Georgia • Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Budesonide / Formoterol, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 40 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatitis C Virus
Interventions: Daclatasvir, BMS-986094, Ribavirin, Placebo for BMS-986094; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Interventions: Tetanus; Biological
Lead sponsor: Robert Krance; Other
Eligibility: 3 Years to 70 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Pulmonary Disease, Chronic Obstructive, Asthma COPD
Interventions: Education and mobile phone text-messaging, Education only; Behavioral · Other
Lead sponsor: Kent State University; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Kent, Ohio

Conditions: Knee Osteoarthritis, Knee Arthritis, Knee Pain Chronic
Interventions: MOTO Medial® UKA; Device
Lead sponsor: Medacta USA; Industry
Eligibility: 18 Years and older
Enrollment: 269 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2025
U.S. locations: 5
States / cities: Lady Lake, Florida • Louisville, Kentucky • Billings, Montana + 2 more

Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: cholecalciferol, arsenic trioxide; Dietary Supplement · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Up to 120 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Heart Failure
Interventions: Sodium Zirconium Cyclosilicate, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 150 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 14
States / cities: National City, California • Stanford, California • Waterbury, Connecticut + 11 more

Conditions: Coronary Artery Chronic Total Occlusion
Interventions: Recanalization of a coronary chronic total occlusion; Device
Lead sponsor: BridgePoint Medical; Industry
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 16
States / cities: Phoenix, Arizona • La Jolla, California • Sacramento, California + 13 more

Conditions: Lung Transplant
Interventions: Belumosudil, Placebo for Belumosudil; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 11
States / cities: Los Angeles, California • Palo Alto, California • Baltimore, Maryland + 8 more

Conditions: End Stage Renal Disease (ESRD), Kidney Failure, Chronic Renal Disease, Hemodialysis
Interventions: InnAVasc Arteriovenous Graft (IG) surgical implant; Device
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 22
States / cities: Phoenix, Arizona • La Mesa, California • Sarasota, Florida + 17 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Venovenous CO2 Removal (VVCO2R) in COPD; Device
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Sickle Cell Disease
Interventions: Guided Relaxation, Acupuncture; Behavioral · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 379 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 5
States / cities: Gainesville, Florida • Atlanta, Georgia • Chicago, Illinois + 2 more

Conditions: Chronic Kidney Disease, Albuminuria
Interventions: Spironolactone, Amiloride; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Breast Cancer, Lung Cancer, Esophageal Cancer, Colon Cancer, Pancreatic Cancer, Liver Cancer, Renal Cancer, Bladder Cancer, Prostate Cancer, Ovarian Cancer, Cervical Cancer, Uterine Cancer
Interventions: Pillars4Life; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasms, Chronic Myelomonocytic Leukemia, Myelofibrosis
Interventions: Ipilimumab, CD25hi Treg depleted DLI; Drug · Biological
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Asthma, COPD
Interventions: beclamethasone dipropionate, albuterol, Prednisone; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Heart Failure, Volume Overload, Decompensated Heart Failure, Systolic Heart Failure
Interventions: Blood Collection, Blood Volume Analysis; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
Interventions: thalidomide, doxorubicin hydrochloride, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Long COVID
Interventions: Maraviroc (MVC), Atorvastatin, 10mg, 20mg, 40mg, Placebo, Maraviroc, Placebo, Atorvastatin; Drug
Lead sponsor: HealthBio, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Cerebrovascular Accident, Chronic Obstructive Pulmonary Disease, Chronic Renal Failure, Coronary Artery Disease, Diabetes Mellitus, Malignant Neoplasm, SARS Coronavirus 2 Infection
Interventions: Best Practice, Tocilizumab; Other · Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Chronic Pain, Hypertension, Diuretics Drug Reactions, SCS
Interventions: Hydrochlorothiazide 12.5mg, Placebo; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 40 Years to 79 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Search by objective public record fields.

MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder

The Influence of Tai Chi Practice on Blood Pressure and Brain Health Among Older Adults With Hypertension (ACTION)

Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo

Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR

Impact of a Mobile Phone and Educational Intervention

Performance of MOTO Medial® Unicompartmental Knee Arthroplasty

Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes

Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure

Facilitated Antegrade Steering Technique in Chronic Total Occlusions (FAST-CTOs)

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease

Venovenous CO2 Removal (VVCO2R) in Patients With COPD and Acute Respiratory Failure

Hybrid Effectiveness-Implementation Trial of Guided Relaxation and Acupuncture for Chronic Sickle Cell Disease Pain

Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease

Pillars4Life Trial

A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

Repeat Emergency Department Visits Among Patients With Asthma and COPD

Assessment of ProEnkephalin to Detect Acute Kidney Injury (AKI)

Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery

A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction